Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2/Phase 3

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

University of Alabama at Birmingham · with National Heart, Lung, and Blood Institute (NHLBI) · NCT04971720

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2, Phase 3
Target enrollment
160
US sites recruiting
1
Study start
February 18, 2022
Record last updated
April 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is broken down in obese individuals. Obese individuals also have lower circulating NP levels. Lower circulating levels of NPs and elevated renin hormone (a part of the Renin-Angiotensin-Aldosterone System [RAAS]) at nighttime may contribute to the high nocturnal blood pressure in obese individuals which puts them at a higher risk of developing CV events. This current study seeks to determine the biological implications of chronopharmacology for synchronizing NP-RAAS-based blood pressure therapy with the physiological diurnal rhythms to restore the normal diurnal rhythm of blood pressure in obese individuals.

Being studied: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet; Valsartan 80 mg Oral Tablet

Conditions: Obesity; Cardiovascular Diseases; Hypertension; Nocturnal Blood Pressure; Natriuretic Peptides; Renin-Angiotensin-Aldosterone System

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age more than or equal to 18 years of age
  • Body Mass Index between 30 to 45 kg/m\^2
  • Blood pressure: Systolic BP more than or equal to 130mmHg and less than or equal to 160mmHg and diastolic blood pressure more than or equal to 80mmHg and less than or equal to 100mmHg. Individuals with hypertension as per the 2017 ACC/AHA Guidelines will be eligible for enrollment

Exclusion Criteria

  • Age less than 18, at screening.
  • Systolic BP \<130 or >160mmHg at baseline, or diastolic BP \<80 or >100 mmHg at baseline
  • BMI \<30 kg/m\^2 or >45 kg/m\^2
  • History of pulmonary hypertension
  • Have any past or present illness of cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, diabetes, stroke, TIA, or seizure.
  • Participants who are taking 3 or more classes of hypertension medications on the maximum dose or with resistant hypertension
  • History of angioedema
  • Estimated glomerular filtration rate (GFR) \< 60 ml/min/1.73 m2 (CKD-EPI equation); urine albumin creatinine ratio ≥30 mg/g
  • Hepatic Transaminase (AST and ALT) levels >3x the upper limit of normal;
  • Significant psychiatric illness
  • Anemia (men, Hct \< 38%; women, Hct \<36%)
  • Participants working night shifts or swing shifts
  • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)

Recruiting US locations

  • University of Alabama at Birmingham

    Birmingham, AL 35294

    Site contact: Nehal Vekariya, MS · 205-934-7173 · nvekariya@uabmc.edu

Study contacts (from the official record)

  • Nehal Vekariya, MS · 205-934-7173 · nvekariya@uabmc.edu
  • Deborah Weber, BSN, RN · 205-975-9964 · dlowe@uabmc.edu
All weight loss studies in Alabama →
PRECISION-BP: Precision Chronopharamacotherapy Targeting… (NCT04971720) | Bored Studies